Tag: Epicutaneous Immunotherapy (EPIT)
DBV Announces Promising 2-Year Results from Ongoing Viaskin “Peanut Patch” Toddler...
81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.
FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial...
The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Skin Patch Immunotherapy Determined Safe and Effective in Toddlers With Peanut...
According to research presented at this year's #ACAAI22 meeting.
Private Law Firm to Investigate Claims on Behalf of Investors in...
It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial
Another delay for the long-awaited therapy.
DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...
Viaskin is testing a new version of their patch designed to address the FDA's concerns.
DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...
Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.
Study Finds Microneedle Delivery Successful in Test of Peanut Allergy Immunotherapy
Study finds five-minute weekly dose of peanut protein through the skin, delivered by a novel microneedle technology, was superior in desensitizing peanut-allergic mice compared to administering the protein through a skin patch.
Viaskin Peanut Patch Therapy Delayed Further as DBV Readies Another Phase...
The patch therapy remains in regulatory limbo.
Safety of Viaskin Peanut Patch Therapy Improved Over 3-Year Study
Reactions decreased over study duration.
